Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection plus TACE for primary hepatic carcinoma
ChiCTR-IPR-15005894Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in Primary Hepatic Carcinoma (PHC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Incidence and severity of adverse reactions. Started Dec 2014; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
Primary Hepatic Carcinoma (PHC)
Beyond the preview
Go deeper on ChiCTR-IPR-15005894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005894.